OOIR: Observatory of International Research

Papers

(The H4-Index of Prostate Cancer and Prostatic Diseases is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer	100
Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL	96
Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level	61
Advances in PSMA-targeted therapy for prostate cancer	53
Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studies	51
A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk	50
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	43
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men	40
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies	39
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis	38
Racial disparities in prostate cancer among black men: epidemiology and outcomes	37
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors	36
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology	36
Management of prostate cancer patients during COVID-19 pandemic	35
3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction	35
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide	35
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review	33
Crosstalk between COVID-19 and prostate cancer	31
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	29
Treating the patient and not just the cancer: therapeutic burden in prostate cancer	29
Clinical considerations for the management of androgen indifferent prostate cancer	28
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study	27
Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer	27
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and networ	27
Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis	26

Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review